What is KLOW peptide?
KLOW is a name used online for a vial sold as KPV, GHK-Cu, BPC-157 and TB-500 together. It is not an approved drug, no human study has tested it, and FDA found no human exposure data for KPV. How much of each is in a draw depends on your label and your water.
| KLOW blend | |
|---|---|
| What it is | KPV, GHK-Cu, BPC-157 and TB-500 as one powder, mixed once with one volume of water |
| United States | Not an FDA-approved drug. None of the four is on FDA's 503A bulks list; FDA reviewers advised against listing KPV (reviewed for use on the skin), BPC-157 and TB-500 in July 2026 [1][2][3][4] |
| Sport (WADA 2026) | WADA's 2026 list names two of the four: BPC-157 (S0) and TB-500 (S2.3), both prohibited at all times. Its S0 class also covers any pharmacological substance with no current approval for human therapeutic use [5] |
| Human evidence | The blend: none. KPV and TB-500: no human exposure data found by FDA [2][4]. GHK-Cu and BPC-157: limited [1][9] |
| Main primary source | FDA briefing document on KPV, July 2026 [2] |
What is KPV, the K in KLOW?
KPV is three amino acids: lysine, proline and valine. FDA's briefing describes it as "a fragment derived from the neuropeptide produced in the pituitary gland called α-melanocyte-stimulating hormone (α-MSH)" [2]. The research behind it is lab and animal work.
The eight articles sent to FDA in support of KPV were all nonclinical [2]. One of them, a 2008 study, used cultured human cells and mice to look at how the peptide gets into gut and immune cells [6].
That is where the evidence stops. When FDA reviewed KPV for possible use in compounding, it wrote: "The nomination did not include, and FDA has not identified, any clinical studies or human exposure data for KPV via any route of administration" [2].
What about the other three peptides?
GHK-Cu is a copper-bound tripeptide [9], BPC-157 is a 15-amino-acid synthetic peptide, and TB-500 is a fragment of thymosin beta-4 [1][4]. GLOW is a name used online for a vial sold as GHK-Cu, BPC-157 and TB-500. Nothing about them changes when KPV is added, except that each now shares the vial with a fourth amount. Our step-by-step reconstitution guide covers the mixing steps.
How do you work out each peptide in a KLOW draw?
The vial is one liquid with four label amounts. Each peptide's strength is its own milligrams divided by the same water volume, and a draw takes the same fraction of all four. On a U-100 syringe, 10 units is 0.1 mL [7].
Arithmetic example, not a dose. The KLOW calculator's starting label is KPV 5 mg, GHK-Cu 50 mg, BPC-157 5 mg and TB-500 10 mg. Mixed with 2 mL, a 10-unit draw is 0.1 mL, which is 5% of the vial. It holds:
| Peptide | Label | Strength in 2 mL | In 10 units |
|---|---|---|---|
| KPV | 5 mg | 2.5 mg/mL | 0.25 mg |
| GHK-Cu | 50 mg | 25 mg/mL | 2.5 mg |
| BPC-157 | 5 mg | 2.5 mg/mL | 0.25 mg |
| TB-500 | 10 mg | 5 mg/mL | 0.5 mg |
That vial gives 20 draws of 10 units, and all four peptides run out on the same one. See this result in the KLOW calculator, then type in your own label.
Same label, three water volumes:
| Water | KPV | GHK-Cu | BPC-157 | TB-500 | Share of vial per 10 units |
|---|---|---|---|---|---|
| 1 mL | 5 mg/mL · 0.5 mg | 50 mg/mL · 5 mg | 5 mg/mL · 0.5 mg | 10 mg/mL · 1 mg | 10% |
| 2 mL | 2.5 mg/mL · 0.25 mg | 25 mg/mL · 2.5 mg | 2.5 mg/mL · 0.25 mg | 5 mg/mL · 0.5 mg | 5% |
| 3 mL | 1.667 mg/mL · 0.167 mg | 16.667 mg/mL · 1.667 mg | 1.667 mg/mL · 0.167 mg | 3.333 mg/mL · 0.333 mg | 3.33% |
Read across a row and the proportions stay put: whatever the water, GHK-Cu is ten times the KPV. Read down a column and only the dilution changes. If your label is different, the KLOW calculator does the same sums for any four amounts.
Why is there no KLOW dose?
No human dose has been established for KLOW or for any of its four peptides.
A dose needs human data, and for two of the four ingredients FDA found none at all: no human exposure data for KPV, none for TB-500 [2][4]. So if you see a KLOW figure online, ask where it came from. We could not find a human study of the blend.
Is KLOW legal, and what are the risks?
In the US, KLOW is not an approved drug, and none of its ingredients is on the 503A bulks list that lets pharmacies compound with a substance [3]. FDA's advisory committee met on 23 July 2026 to consider KPV, BPC-157 and TB-500 for that list [10]. FDA's reviewers wrote that "a balancing of the criteria weighs against" each of the three [1][2][4]. FDA has said it will not make a final decision until the committee's input and its own reviews are finished [8].
On 30 October 2026, the HHS Office of the Secretary published notice of a draft enforcement policy for compounding with "certain peptide bulk drug substances" while the 503A bulks list is developed through rulemaking [11]. Under this interim policy, HHS "does not intend to take enforcement action" against state-licensed pharmacies, federal facilities or licensed physicians compounding with a peptide in the policy's Appendix A, and may revisit that if a safety signal or quality problem arises [11]. The notice does not name the peptides; Appendix A is in the policy document on the HHS website. It adds no peptide to the bulks list, is not an approval and "does not establish any rights for any person" [11]. We found no final rule published as of 12 November 2026.
For BPC-157 and TB-500, FDA raised concern about immune reactions, which clumping and impurities can make worse, especially after injection [1][4]. For KPV, reviewed for use on the skin, FDA's main concern was the lack of any human data, including data on immune reactions [2]. A four-peptide vial adds a problem of its own. If something goes wrong, there is no way to tell which of the four caused it: of a two-peptide product, FDA wrote that "because the product contained two peptides it is not possible to assess a potential relationship between BPC-157 and the reported AEs" [1].
For competitive athletes the answer is simpler. WADA's 2026 list names two of the four, BPC-157 (S0) and TB-500 (S2.3), both prohibited at all times. Its S0 class also covers any pharmacological substance with no current approval for human therapeutic use [5].
How PinPoint records this
PinPoint does not list KLOW as a compound. It lists KPV, GHK-Cu, BPC-157 and TB-500 separately, so one KLOW draw can be logged as four entries. The website's KLOW calculator works out the milligrams of each. Logging is part of PinPoint Pro.
Four entries keep four separate histories. If you later want to know how much KPV you logged in a month, the answer is there, which a single line called "KLOW" could never tell you. Each compound's status is the regulators' position given above. PinPoint records the values you enter and never recommends a dose.
Get PinPoint on the App StoreWhere do these facts come from?
- FDA. Briefing document, BPC-157-related bulk drug substances, Pharmacy Compounding Advisory Committee, 23-24 July 2026. https://www.fda.gov/media/193343/download
- FDA. Briefing document, KPV-related bulk drug substances, Pharmacy Compounding Advisory Committee, 23-24 July 2026. https://www.fda.gov/media/193346/download
- FDA. Bulk drug substances used in compounding under section 503A of the FD&C Act (content current as of 14 May 2026). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
- FDA. Briefing document, TB-500-related bulk drug substances, Pharmacy Compounding Advisory Committee, 23-24 July 2026. https://www.fda.gov/media/193349/download
- World Anti-Doping Agency. Prohibited List 2026, sections S0 and S2.3. https://www.wada-ama.org/en/prohibited-list
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008. PubMed 18061177. https://pubmed.ncbi.nlm.nih.gov/18061177/
- FDA 510(k) summary K233794, insulin syringe: "U-100 means there are 100 units of insulin in every mL." https://www.accessdata.fda.gov/cdrh_docs/pdf23/K233794.pdf
- FDA. Briefing document introduction, Pharmacy Compounding Advisory Committee, 23-24 July 2026. https://www.fda.gov/media/193342/download
- FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of 22 April 2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (meeting page and agenda). https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- HHS, Office of the Secretary. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability of a draft policy). Federal Register, 30 October 2026, 91 FR 68526, document 2026-22192, docket HHS-OASH-2026-0496. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
Updated . Last editorial review by The PinPoint team
